Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

INTERCEPT Verification and validation of a biomarker panel that identifies individuals at high risk to develop Crohn’s disease allowing INTERCEPTION of full-blown disease development

Coordinator
Stichting Amsterdam Umc, Netherlands
Runs
1 January 2025 to 31 December 2029
Status
Running
EU funding
€15.2m
Total cost
€38.0m
Partners
25 organisations in 16 countries
Type
Research and Innovation Action
Grant agreement
101194780

What the project is doing

In the project's own words, from its summary on CORDIS.

Chronic inflammatory diseases such rheumatoid arthritis (RA), multiple sclerosis (MS), type 1 diabetes (t1D) and Crohn’s disease (CD) are increasingly common and cause important loss of quality of life and work productivity. Most of these conditions are diagnosed at a late stage of the disease; many patients have complications at diagnosis. For many of these conditions there are now methods or markers in the blood that allow diagnosis in the preclinical phase, meaning that individuals can be identified that have the disease but not yet the symptoms.

This would allow very early treatment (which is highly effective) that prevents development of complications, which has been done successfully in RA, MS and t1D. CD mainly affects adolescents/young adults in the most productive phase of life. At diagnosis the majority of patients has fistulas (painful holes around the anus), stenosis of the bowel leading to crampy pain and metabolic symptoms such as weight loss, iron deficiency and other nutritional deficiencies.

In CD, a number of molecules (‘markers’) have been identified in the blood of individuals up to 7 years before diagnosis. In the current project we wish to verify these markers in North American and European cohorts of which we have the serum available in freezers with the help of advanced laboratory tests leading to a ‘serum signature’. An algorithm will incorporate the relative importance of the different proteins to make it ready for widespread use.

Then, we will test this signature in 10000 first degree relatives of European patients with CD across 7 countries, a process that is named ‘prospective validation’. In a final step we will demonstrate that if individuals are identified with the biomarker, CD symptom development can be halted (‘intercepted’) with medical treatment. If we succeed in this scientific work, the impact for the community would be enormous. We would be able to prevent suffering, surgeries, disability and loss of productivity significantly.

Who is involved

OrganisationCityCountryRole
Stichting Amsterdam UmcAmsterdamNetherlandsCoordinator
United European Gastroenterology GmbHViennaAustriaParticipant
International Federation of Crohn's and Ulcerative Colitis AssociationsBruxelles / BrusselBelgiumParticipant
Takeda Pharmaceuticals International AGGlattparkSwitzerlandParticipant
Eurice European Research and Project Office GmbHSt IngbertGermanyParticipant
Aalborg UniversitetAalborgDenmarkParticipant
Grupo Espanol De Trabajo En Enfermedad De Crohn Y Colitis Ulcerosa GettecuBilbaoSpainParticipant
Centre Hospitalier Regional Et Universitaire De LilleLilleFranceParticipant
Fondazione Policlinico Universitario Agostino Gemelli IrccsRomaItalyParticipant
Gemelli Digital Medicine & Health SRLRomaItalyThird party
Celltrion IncIncheonSouth KoreaParticipant
Academisch Ziekenhuis GroningenGroningenNetherlandsParticipant
Amsterdam Umc Research BVAmsterdamNetherlandsThird party
Richard VeselyLarenNetherlandsParticipant
Stichting VuAmsterdamNetherlandsParticipant
Norges Teknisk-Naturvitenskapelige Universitet NTNUTrondheimNorwayParticipant
Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych I AdministracjiWarszawaPolandParticipant
Glsmed Learning Health SALisboaPortugalParticipant
Hospital Da Luz SALisboaPortugalThird party
Orebro Lans LandstingOrebroSwedenThird party
Orebro UniversityOrebroSwedenParticipant
Ludger LimitedAbingdonUnited KingdomParticipant
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomParticipant
Icahn School of Medicine at Mount SinaiNew YorkUnited StatesParticipant
Prometheus Laboratories IncSan DiegoUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI